Harvard Apparatus Regenerative Technology Schedules Release Of Second Quarter 2015 Financial Results And Investor Teleconference For August 13th

Conference Call to Occur at 5:00PM ET That Day

HOLLISTON, Mass.--(BUSINESS WIRE)--Harvard Apparatus Regenerative Technology, Inc. (NASDAQ: HART), a biotechnology company developing bioengineered organs for life-threatening conditions, will announce results of its second quarter ended June 30, 2015 after -market trading hours on Thursday, August 13, 2015, as well as a commentary by Jim McGorry, the company’s newly-appointed CEO, on the company’s business outlook. A conference call to discuss the company’s second quarter results and business outlook is scheduled for that same day at 5:00 PM (Eastern Time). On that call, management may respond to questions from the audience on any of a number of topics related to the business, including clinical and preclinical research, operations, plans and outlook.

Participating in the call will be Jim McGorry, Chief Executive Officer, Saverio La Francesca, M.D., Executive Vice President and Chief Medical Officer and Tom McNaughton, Chief Financial Officer, of HART.

Investors can access the live conference call by dialing the following phone numbers: toll-free 877-407-8293, or international: 201-689-8349, and referencing Harvard Apparatus Regenerative Technology, Inc. An audio webcast will also be available at http://public.viavid.com/index.php?id=115675

If you are unable to listen to the live conference call, a replay will be available within approximately 3 hours from the end of the call through 11:59pm ET on August 20, 2015 and will be accessible by dialing toll-free 877-660-6853, or toll/international 201-612-7415, and referencing conference ID “13615845”. The replay will also be made available at the web link above and on the company’s web site, www.harvardapparatusregen.com.

About Harvard Apparatus Regenerative Technology

Harvard Apparatus Regenerative Technology makes bioengineered organs for life-threatening conditions. Our technology platform is to be used to restore the function of the airways and the esophagus. Our first product, the HART-Trachea, is intended to replace or repair a trachea that has been severely damaged by either physical trauma or trachea cancer. Our HART-Trachea technology has been used in several human trachea transplants to date approved under compassionate use exemptions, but none of our products are yet approved by a government regulatory authority for marketing. The trademark “Harvard Apparatus” is used under a sublicense agreement with Harvard Bioscience, who has licensed the right to use such trademark from Harvard University.